Jump to main content
US EPA
United States Environmental Protection Agency
Search
Search
Main menu
Environmental Topics
Laws & Regulations
About EPA
Health & Environmental Research Online (HERO)
Contact Us
Print
Feedback
Export to File
Search:
This record has one attached file:
Add More Files
Attach File(s):
Display Name for File*:
Save
Citation
Tags
HERO ID
6114786
Reference Type
Journal Article
Title
Anti-inflammatory effect of a new piperazine derivative: (4-methylpiperazin-1-yl)(1-phenyl-1H-pyrazol-4-yl)methanone
Author(s)
Batista, DC; Silva, DPB; Florentino, IF; Cardoso, CS; Gonçalves, MP; Valadares, MC; Lião, LM; Sanz, G; Vaz, BG; Costa, EA; Menegatti, R
Year
2018
Is Peer Reviewed?
Yes
Journal
InflammoPharmacology
ISSN:
0925-4692
EISSN:
1568-5608
Volume
26
Issue
1
Page Numbers
217-226
Language
English
PMID
28825161
DOI
10.1007/s10787-017-0390-8
Web of Science Id
WOS:000423397700018
Abstract
AIMS:
This study investigates the anti-nociceptive and anti-inflammatory effects of new piperazine compound (LQFM182) as well as the toxicity acute in vitro.
MAIN METHODS:
To evaluate the anti-nociceptive activity, the acetic acid-induced abdominal writhing test, tail flick test and formalin-induced pain test were used. The anti-inflammatory activity was evaluated using the models of paw oedema and pleurisy induced by carrageenan and some inflammatory parameters were evaluated, including cell migration, myeloperoxidase enzyme activity and the levels of TNF-α and IL-1β cytokines in pleural exudate. The acute oral systemic toxicity of LQFM182 in mice was evaluated through the neutral red uptake (nru) assay.
KEY FINDINGS:
LQFM182 (50, 100 or 200 mg/kg, p.o.) decreased the number of writhings induced by acetic acid in a dose-dependent manner, and an intermediate dose (100 mg/kg, p.o.) reduced the paw licking time of animals in the second phase of the formalin test. Furthermore, LQFM182 (100 mg/kg, p.o.) reduced oedema formation at all hours of the paw oedema induced by carrageenan test and in pleurisy test reduced cell migration from the reduction of polymorphonuclear cells, myeloperoxidase enzyme activity and the levels of pro-inflammatory cytokines IL-1β and TNF-α. Therefore, it was classified in GHS category 300 < LD50 < 2000 mg/kg.
SIGNIFICANCE:
Reduction of the TNF-α and IL-1β levels.
Keywords
; Analgesics/pharmacology; Animals; Anti-Inflammatory Agents/pharmacology; BALB 3T3 Cells; Carrageenan/pharmacology; Cell Line; Cell Movement/drug effects; Edema/chemically induced; Edema/drug therapy; Edema/metabolism; Female; Interleukin-1beta/metabolism; Mice; Pain/drug therapy; Pain/metabolism; Pain Measurement/methods; Piperazine; Piperazines/pharmacology; Pleurisy/drug therapy; Pleurisy/metabolism; Pyrazoles/pharmacology; Tumor Necrosis Factor-alpha/metabolism; Index Medicus/
Tags
IRIS
•
Formaldehyde
HAWC
Respiratory tract pathology human
Excluded
Search Update 2018-2021
Human Respiratory Pathology
PubMed
Home
Learn about HERO
Using HERO
Search HERO
Projects in HERO
Risk Assessment
Transparency & Integrity